The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder.
Addict Biol
; 29(2): e13369, 2024 02.
Article
en En
| MEDLINE
| ID: mdl-38380709
ABSTRACT
Here, we present recent studies suggesting that specific DRD3 single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that DRD3 SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Receptores Dopaminérgicos
/
Trastornos Relacionados con Opioides
Límite:
Humans
Idioma:
En
Revista:
Addict Biol
Asunto de la revista:
TRANSTORNOS RELACIONADOS COM SUBSTANCIAS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos